ArticleCost effectiveness and resource allocation : C/E2025
Economic evaluation of generic inhalational bronchodilators from the Jan-Aushadi scheme versus branded alternatives.
Article in Cost effectiveness and resource allocation : C/E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn India, the burden of respiratory diseases has brought about a need for the use of inhalational bronchodilators, which often pose a financial strain for a significant portion of the underprivileged population. Hence Jan Aushadhi initiative makes available quality drugs at affordable prices through dedicated stores through-out India. The objective of this study was to perform a cost comparison study of generic inhalational bronchodilators provided through Jan Aushadi pharmacies versus their branded counterparts.
methodsThe cost of Jan Aushadi drugs and the cost of the most expensive and cheapest marketed branded drugs for the same molecule and dose were ascertained and presented in Indian rupees. The cost difference, cost ratio and cost variance were calculated by comparing the price of Jan Aushadi generic drugs with the most expensive and cheapest branded drugs in the same category.
resultsCompared to branded drugs, all the Jan Aushadi generic drugs were cheaper, except one (SALMETROL). The highest cost difference was observed for Tiotropium Bromide, while the least was observed for Salmetrol (25mcg). The highest cost ratio (5.55) and cost variance (455.454) were observed for Tiotropium Bromide (9 mcg). INTERPRETATION AND
conclusionsThe current study compares the cost difference between the branded Inhalational bronchodilators on the market and Jan Aushadhi generic inhalational bronchodilators. Replacing the costly branded bronchodilators with Jan Aushadhi generic drugs can result in substantial cost savings. By conducting a cost comparison, decision makers can gain insights into the financial implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.